Selitrectinib
Selitrectinib (LOXO-195) is a next-generation TRK kinase inhibitor, with IC50s of 0.6 nM and TRKA and TRKC, respectively[1].
Product Specifications
CAS Number
[2097002-61-2]
Product Name Alternative
LOXO-195
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Trk Receptor
Type
Reference compound
Related Pathways
Neuronal Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/LOXO-195.html
Concentration
10mM
Purity
99.90
Solubility
DMSO : 62.5 mg/mL (ultrasonic)
Smiles
FC1=CN=C(CC[C@H](N2)C)C([C@](CCC3)([H])N3C(C=CN4N=C5)=NC4=C5C2=O)=C1
Molecular Formula
C20H21FN6O
Molecular Weight
380.42
Precautions
H302, H315, H319, H335
References & Citations
[1]Drilon A, et al. A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors. Cancer Discov. 2017 Sep;7 (9) :963-972.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Isoform
TrkA; TrkC
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items